Founded in 2017, Nu Eyne is a leading company with the largest research results in the field of electroceuticals in Korea.
Eye disease was selected as the first indication to demonstrate the best performance of electroceuticals, completing the commercialization in 2020. It plans to expand its product line from tinnitus, sleep disorder, anti-cancer to mental illness by 2025.
In 2021, Nu Eyne signed an MOU with NeuroVenti to develop electronic drugs for brain development disorders such as ADHD and ASD. And in 2022, they signed a contract to exclusively distribute migraine treatment devices with B&K.